LDX.ASX: Lumos Receives FebriDx Order from PHASE Scientific

Lumos Receives FebriDx Order from PHASE Scientific

Stock	Lumos Diagnostics Holdings Ltd (LDX.ASX)
Release Time	4 Aug 2026, 9:04 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Lumos Diagnostics Receives $767,800 FebriDx Order from PHASE Scientific

Key Points

Lumos Diagnostics received a $767,800 FebriDx order from PHASE Scientific
Order is part of a $5.0 million prepayment milestone
Delivery will be fulfilled progressively until October 2026

Full Summary

Lumos Diagnostics Holdings Ltd, a leader in rapid, point-of-care diagnostic technologies, announced it has received a US$767,800 FebriDx purchase order from PHASE Scientific. The order is the initial one associated with the US$5.0 million prepayment milestone received by Lumos following the grant of CLIA waiver for FebriDx by the U.S. FDA on 27 March 2026. Product delivery will be fulfilled progressively between now and October 2026, with revenue recognized upon shipment. The order satisfies part of the Year 1 minimum order quantity commitment under the distribution agreement with PHASE Scientific.

Outlook

Lumos Diagnostics looks forward to supporting the continued adoption of rapid, point-of-care acute respiratory infection testing across the U.S. market.